Startup MagIA tackles hepatitis B

MagIA, founded in August 2017 to bring research conducted at G2Elab and LMGP to the market, has just been ranked by Challenges magazine as one of 100 startups to invest in in 2018. The company is developing a portable, ultra-fast immunological test kit. The kit can complete a test—one that would traditionally require drawing blood and about two hours in the lab—from a few drops of blood in just fifteen minutes.

The company, which currently has five employees, is now focusing on developing a test for hepatitis B, a disease that affects 250 million people worldwide, mainly in Africa, Southeast Asia, and China. MagIA is also working on a home test kit for chronic kidney disease with the support of the Auvergne-Rhône-Alpes regional government. The company plans to raise €1 million from investors in late 2018.

Contact: orphee.cugat@g2elab.grenoble-inp.fr,  paul.kauffmann@magia-diagnostics.com

Facebook

Twitter